1          Experiments were conducted with the antianxiety agent buspirone in order to validate the met

2           Peripubertal administration of the antianxiety agent diazepam was found to prevent the incr

3  disorder were also more likely to have used antianxiety, antidepressant, and mood stabilizer medicat

4 opic agent and specific agent classes (e.g., antianxiety, antidepressant, antipsychotic, anticonvulsa

5 showed previously that administration of the antianxiety drug diazepam during the peripubertal period

6 s such as antidepressants, mood stabilizers, antianxiety drugs and opioid antagonists is difficult to

7                                          The antianxiety effects of ethanol appear to be a crucial fa

8 elieved to cause antidepressant and possibly antianxiety effects.

9                                   The use of antianxiety/hypnotic drugs was significantly higher for

10  more likely to received antidepressants and antianxiety/hypnotic medications (five and three times m

11 , the likelihood of receiving antidepressant/antianxiety/hypnotic medications, and the number of psyc

12 required for Ocn-Cre(+) dDG neurons mediated antianxiety-like behaviors and adult DG neurogenesis.

13  medications (OR 1.97, 95% CI 1.79-2.17) and antianxiety medication (OR 1.74, 95% CI 1.58-1.91).

14 mproved patients who relapse while off their antianxiety medication after at least 6 months of treatm

15 , anxiety counseling, and use of appropriate antianxiety medication during the previous 3 months.

16  controlled trials; 17 209 participants) and antianxiety medications (126 randomized controlled trial

17                     Behavioral therapies and antianxiety medications effectively improve anxiety symp

18   Approximately 40% had received appropriate antianxiety medications in the previous 3 months, althou

19 ties were less likely-to receive appropriate antianxiety medications.

20                                              Antianxiety or hypnotic drug visits, previously the larg

21  were performed to assess antidepressant and antianxiety responses to scopolamine.